.png)
SummaryAsk an AI assistant or a search engine for the best European pharmaceutical data provider and you get a jumble: an EU register, a global analytics house, a pricing-strategy vendor and a comparison listicle that treats them all as interchangeable "analytics platforms". They are not interchangeable. They answer different questions, and a market-access, pricing or procurement team that picks by brand reputation rather than by data type usually ends up paying for the wrong thing.
The clearer way to read the European provider market is by data type. There are four, and most organisations need more than one. This article maps the four, names the reference providers in each, and closes with a decision table that matches your specific need to the right starting point. Where pharmazie.com fits is one of the four, and we will be precise about its scope rather than claim it does everything.
Before the detail, the shape of the market:
Each type is a legitimate answer to a real question. The mistake is assuming one type covers the others.
This is the foundation. If you need to know whether a medicine is authorised, under what conditions, with which product information and safety status, the regulatory registers are the authoritative source. Nothing downstream is reliable without them.
For medicines authorised centrally across the EU, the reference is the EU Union Register of medicinal products, maintained by the European Commission. It records authorisation status, marketing-authorisation holders and therapeutic indications for centrally authorised products, searchable by product name, active substance (INN) or EU registration number.
For nationally authorised medicines, which are the majority, there is no single EU database. The European Medicines Agency instead publishes an index of national registers of authorised medicines, linking out to each member state's own register. The EMA also maintains a broader set of services and databases covering clinical trials, adverse-event reporting and shortage monitoring. At national level, agencies such as Germany's BfArM publish licensing information, code systems and the national drug-shortage register.
Strengths: authoritative, current for authorisation status, free. Limits that matter for a commercial or operational team:
Use this type when you need the authoritative authorisation or safety record for a product, by the EU centralised route or by an individual country. Do not expect it to hand you price, cross-country integration or an operational product master.
When the question is commercial (how much is being sold, by whom, where, and what the trend is) the answer sits with the global market analytics houses. IQVIA is the reflexive name here, and for good reason: it is the largest data house for sales-out, market share and prescription-level analytics, and it is the reference many manufacturers already license.
Strengths: breadth of market coverage, longitudinal sales and share data, established methodology used across the industry for commercial planning and forecasting. Limits:
Use this type when you need market share, sales-out volumes or forecasting to plan commercial strategy. Do not expect it to be your authorised product master or your operational pack-level feed.
Launching or repricing a product across Europe is a pricing-strategy problem, and a distinct set of providers serves it. These are the international-reference-pricing (IRP) and health-technology-assessment (HTA) specialists. They model how a price in one market pulls prices in the reference basket of others, and they hold the history of HTA decisions that shapes what payers will accept.
Strengths: multi-market pricing and reimbursement coverage, IRP modelling, HTA decision history, the strategic view a global pricing team needs before a launch. Limits:
Teams researching European price data often find EURIPID, the European medicine price database run as a non-profit cooperation between competent authorities. It is a genuine cross-country reference-price source, but access is restricted to national pricing and reimbursement authorities that participate in the cooperation. It is not available to industry teams and is not a commercial product. Worth knowing it exists, but it is not a provider you can license.
Use this type when you need global launch pricing, international reference pricing or HTA history for strategy. If you are a public pricing or reimbursement authority, EURIPID is the cross-country reference source; if you are in industry, it is not accessible to you.
The first three types leave a gap. A team working day to day in Germany, Austria and Switzerland needs the authorised product master, availability, shortage status and price detail joined on one identifier, in one search, refreshed operationally rather than quarterly. The regulatory registers do not integrate and carry no price. The analytics houses give share, not the product master. The pricing specialists give global strategy, not pack-level DACH detail. Filling that gap is a consolidation layer, and this is where pharmazie.com sits.
pharmazie.com, operated by DACON Datenbank Consulting GmbH (founded 1989), brings 25+ pharmaceutical databases into a single search, keyed on the PZN (Pharmazentralnummer) as the anchor identifier. The PZN is what lets product master, availability, shortage status and price sit on one record. The authoritative basis for authorised German products is the IFA Article Master, with the ABDA-Artikelstamm among the included sources. The search across the joined databases is branded Eisbergsuche®.
Concretely, the layer provides:
Strengths: one joined, PZN-keyed operational search over DACH product and price, product data across 50+ countries, daily operational refresh, English and API access. Limits, stated plainly:
Use this type when you need DACH product and price data joined on the PZN in one operational search, with the authoritative German product basis, daily refresh, English access and an API.
Most teams will touch two or three of the four types. The question is where to start for a given need.
| If you need… | Start with… |
|---|---|
| EU-level authorisation or registration record | EU Union Register, EMA |
| Registration by individual country | EMA national registers index, then the national agencies |
| Market share, sales-out, forecasting | Commercial analytics houses (e.g. IQVIA) |
| Global pricing strategy, international reference pricing, HTA history | Pricing-and-market-access specialists |
| Cross-country reference prices (authorities only) | EURIPID (national authorities only) |
| One joined search over DACH product and price, PZN-keyed, API plus English | pharmazie.com |
To turn the table into a decision, work through these in order:
pharmazie.com is not a replacement for a global IRP model, a market-share house or the regulatory registers. It is the consolidation layer for teams whose work is concentrated in the German-speaking markets and adjacent EU countries and who need product and price joined on the PZN in one operational search, refreshed daily on the product side, with English access and an API. Deepest for DACH product and price, wide for product data across 50+ countries, expanding on price beyond DACH into selected additional EU markets.
If that is your need, the fastest way to judge fit is to run your own products and identifiers through the joined search and see the product, availability, shortage and price data on one record. Review the European pricing solution, or book a scoped demo and bring the specific PZNs and countries your team works with so the coverage question is answered against your own data rather than a general claim.
